Potential Biomarkers of Obesity

For obesity with cardiovascular diseases:

Peterson, S. J., Shapiro, J. I., Thompson, E., Singh, S., Liu, L., Weingarten, J. A., … Abraham, N. G. (2019). Oxidized HDL, Adipokines, and Endothelial Dysfunction: A Potential Biomarker Profile for Cardiovascular Risk in Women with Obesity. Obesity (Silver Spring, Md.), 27(1), 87–93. https://doi.org/10.1002/oby.22354

Ahmad, A., Memon, A. A., Sundquist, J., Svensson, P. J., Zöller, B., & Sundquist, K. (2018). Fat mass and obesity-associated gene rs9939609 polymorphism is a potential biomarker of recurrent venous thromboembolism in male but not in female patients. Gene, 647, 136–142. https://doi.org/10.1016/j.gene.2018.01.013

Popovic, D. S., Mitrovic, M., Tomic-Naglic, D., Icin, T., Bajkin, I., Vukovic, B., … Stokic, E. (2017). The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity. Current Neurovascular Research, 14(3), 200–206. https://doi.org/10.2174/1567202614666170619080526

Baumann, S., Koepp, J., Becher, T., Huseynov, A., Bosch, K., Behnes, M., … Akin, I. (2016). Biomarker evaluation as a potential cause of gender differences in obesity paradox among patients with STEMI. Cardiovascular Revascularization Medicine: Including Molecular Interventions, 17(2), 88–94. https://doi.org/10.1016/j.carrev.2015.12.012

For obesity with liver diseases:

Mesarwi, O. A., Shin, M.-K., Drager, L. F., Bevans-Fonti, S., Jun, J. C., Putcha, N., … Polotsky, V. Y. (2015). Lysyl Oxidase as a Serum Biomarker of Liver Fibrosis in Patients with Severe Obesity and Obstructive Sleep Apnea. Sleep, 38(10), 1583–1591. https://doi.org/10.5665/sleep.5052

For obesity with autoimmune diseases and cancer:

Dalamaga, M., & Christodoulatos, G. S. (2015). Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies. Hormone Molecular Biology and Clinical Investigation, 23(1), 5–20. https://doi.org/10.1515/hmbci-2015-0016

Perl, A. (2015). mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Annals of the New York Academy of Sciences, 1346(1), 33–44. https://doi.org/10.1111/nyas.12756

For obesity with metabolic disorders:

Maltais-Payette, I., Boulet, M.-M., Prehn, C., Adamski, J., & Tchernof, A. (2018). Circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations. Nutrition & Metabolism, 15, 78. https://doi.org/10.1186/s12986-018-0316-5

Larsen, M. A., Isaksen, V. T., Moen, O. S., Wilsgaard, L., Remijn, M., Paulssen, E. J., … Goll, R. (2018). Leptin to adiponectin ratio – A surrogate biomarker for early detection of metabolic disturbances in obesity. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD, 28(11), 1114–1121. https://doi.org/10.1016/j.numecd.2018.06.020

Balampanis, K., Chasapi, A., Kourea, E., Tanoglidi, A., Hatziagelaki, E., Lambadiari, V., … Sotiropoulou-Bonikou, G. (2018). Inter-tissue expression patterns of the key metabolic biomarker PGC-1α in severely obese individuals: Implication in obesity-induced disease. Hellenic Journal of Cardiology: HJC = Hellenike Kardiologike Epitheorese. https://doi.org/10.1016/j.hjc.2018.08.002

Fanelli, F., Mezzullo, M., Repaci, A., Belluomo, I., Ibarra Gasparini, D., Di Dalmazi, G., … Pagotto, U. (2018). Profiling plasma N-Acylethanolamine levels and their ratios as a biomarker of obesity and dysmetabolism. Molecular Metabolism, 14, 82–94. https://doi.org/10.1016/j.molmet.2018.06.002

O’Neill, S., Larsen, M. B., Gregersen, S., Hermansen, K., & O’Driscoll, L. (2018). miR-758-3p: a blood-based biomarker that’s influence on the expression of CERP/ABCA1 may contribute to the progression of obesity to metabolic syndrome. Oncotarget, 9(10), 9379–9390. https://doi.org/10.18632/oncotarget.24314

Tacke, C., Aleksandrova, K., Rehfeldt, M., Murahovschi, V., Markova, M., Kemper, M., … Rudovich, N. (2018). Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. Journal of Cell Communication and Signaling, 12(3), 539–548. https://doi.org/10.1007/s12079-017-0427-1

Mojbafan, M., Afsartala, Z., Amoli, M. M., Mahmoudi, M., Yaghmaei, P., Larijani, B., & Ebrahim-Habibi, A. (2017). Liver alpha-amylase gene expression as an early obesity biomarker. Pharmacological Reports: PR, 69(2), 229–234. https://doi.org/10.1016/j.pharep.2016.11.001

Al Haj Ahmad, R. M., & Al-Domi, H. A. (2017). Complement 3 serum levels as a pro-inflammatory biomarker for insulin resistance in obesity. Diabetes & Metabolic Syndrome, 11 Suppl 1, S229–S232. https://doi.org/10.1016/j.dsx.2016.12.036

Horakova, O., Hansikova, J., Bardova, K., Gardlo, A., Rombaldova, M., Kuda, O., … Kopecky, J. (2016). Plasma Acylcarnitines and Amino Acid Levels As an Early Complex Biomarker of Propensity to High-Fat Diet-Induced Obesity in Mice. PloS One, 11(5), e0155776. https://doi.org/10.1371/journal.pone.0155776

Lau, E., Marques, C., Pestana, D., Santoalha, M., Carvalho, D., Freitas, P., & Calhau, C. (2016). The role of I-FABP as a biomarker of intestinal barrier dysfunction driven by gut microbiota changes in obesity. Nutrition & Metabolism, 13, 31. https://doi.org/10.1186/s12986-016-0089-7

Voigt, A., Ribot, J., Sabater, A. G., Palou, A., Bonet, M. L., & Klaus, S. (2015). Identification of Mest/Peg1 gene expression as a predictive biomarker of adipose tissue expansion sensitive to dietary anti-obesity interventions. Genes & Nutrition, 10(5), 27. https://doi.org/10.1007/s12263-015-0477-z

This entry was posted in Bioinformatics, Biomarkers, Mind-Body, Systems Medicine and tagged , , , , , , , . Bookmark the permalink.

Leave a Reply